Peptide-MHC Class II Dimers as Therapeutics to Modulate Antigen-Specific T Cell Responses in Autoimmune Diabetes

Journal of Immunology

Volumn 171, Issue 10, 2003, Pages 5587-5595

  Masteller, Emma L ^a   Warner, Matthew R ^a   Ferlin, Walter ^b   Judkowski, Valeria ^c   Wilson, Darcy ^c   Glaichenhaus, Nicolas ^b   Bluestone, Jeffrey A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BDC2.5 PEPTIDE IA G7; DIMER; GAMMA INTERFERON; HYBRID PROTEIN; INTERLEUKIN 10; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE DERIVATIVE; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNE DISEASE; CELL DEATH; CELL SURVIVAL; CLONAL ANERGY; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TRANSGENIC MOUSE;

EID: 0242494202     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.171.10.5587     Document Type: Article

References (35)

1. Cooke, A., J. M. Phillips, and N. M. Parish. 2001. Tolerogenic strategies to halt or prevent type I diabetes. Nat. Immun. 2:810.
2. Masteller, E. L., and J. A. Bluestone. 2002. Immunotherapy of insulin-dependent diabetes mellitus. Curr. Opin. Immunol. 14:652.
3. Sloan-Lancaster, J., and P. M. Allen. 1996. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu. Rev. Immunol. 14:1.
4. Smith, J. A., J. Y. Tso, M. R. Clark, M. S. Cole, and J. A. Bluestone. 1997. Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy. J. Exp. Med. 185:1413.
5. Herold, K. C., J. A. Bluestone, A. G. Montag, A. Parihar, A. Wiegner, R. E. Gress, and R. Hirsch. 1992. Prevention of autoimmune diabetes with non-activating anti-CD3 monoclonal antibody, Diabetes 41:385.
6. Chatenoud, L., E. Thervet, J. Primo, and J. Bach. 1994. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc. Natl. Acad. Sci. USA 91:123.
7. Chatenoud, L., J. Primo, and J. Bach. 1997. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J. Immunol. 158:2947.
8. Smith, J. A., Q. Tang, and J. A. Bluestone. 1998. Partial TCR signals delivered by FcR-nonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets. J. Immunol. 160:4841.
9. Chatenoud, L. 2003. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat. Rev. Immunol. 3:123.
10. Herold, K. C., W. Hagopian, J. A. Auger, E. Poumian-Ruiz, L. Taylor, D. Donaldson, S. E. Gitelman, D. M. Harlan, D. Xu, R. A. Zivin, and J. A. Bluestone. 2002. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346:1692.
11. Kozono, H., J. While, J. Clements, P. Marrack, and J. Kappler. 1994. Production of soluble MHC class II proteins with covalently bound single peptides. Nature 369:151.
12. Eisenbarth, G. S., and G. T. Nepom. 2002. Class II peptide multimers: promise for type 1A diabetes? Nat. Immun. 3:344.
13. Hackett, C. J., and O. K. Sharma. 2002. Frontiers in peptide-MHC class II multimer technology. Nat. Immun. 3:887.
14. Hamad, A. R. A., S. M. O'Herrin, M. S. Lebowitz, A. Srikrishnan, J. Bieler, J. Schneck, and D. Pardoll. 1998. Potent T cell activation with dimeric peptide-major histocompatibility complex class II ligand: the role of CD4 coreceptor. J. Exp. Med. 188:1633.
15. Casares, S., C. S. Zong, D. L. Radu, A. Miller, C. A. Bona, and T.-D. Brumeanu. 1999. Antigen-specific signaling by a soluble, dimeric peptide/major histocompatibility complex class II/Fc chimera leading to T helper cell type 2 differentiation. J. Exp. Med. 190:543.
16. Appel, H., N. P. Seth, L. Gauthier, and K. W. Wucherpfennig. 2001. Anergy induction by dimeric TCR ligands. J. Immunol. 166:5279.
17. Cochran, J. R., T. O. Cameron, and L. J. Stern. 2000. The relationship of MHC-peptide binding and T cell activation probed using chemically defined MHC class II oligomers. Immunity 12:241.
18. Zuo, L., C. M. Cullen, M. L. DeLay, S. Thornton, L. K. Myers, E. F. Rosloniec, G. P. Boivin, and R. Hirsch. 2002. A single-chain class II MHC-IgG3 fusion protein inhibits autoimmune arthritis by induction of antigen-specific hyporesponsiveness. J. Immunol. 168:2554.
19. + T cells by a soluble dimeric peptide-MHC class II chimera. Nat. Immun. 3:383.
20. + islet-specific T cell clone. Science 249:1433.
21. Katz, J. D., C. Benoist, and D. Mathis. 1995. T helper cell subsets in insulin-dependent diabetes. Science 268:1185.
22. Haskins, K., M. Portas, B. Bergman, K. Lafferty, and B. Bradley. 1989. Pancreatic islet-specific T-cell clones from nonobese diabetic mice. Proc. Natl. Acad. Sci. USA 86:8000.
23. Judkowski, V., C. Pinilla, K. Schroder, L. Tucker, N. Sarvetnick, and D. B. Wilson. 2001. Identification of MHC class II-restricted peptide ligands, including a glutamic acid decarboxylase 65 sequence, that stimulate diabetogenic T cells from transgenic BDC2.5 nonobese diabetic mice. J. Immunol. 166:908.
24. Katz, J. D., B. Wang, K. Haskins, C. Benoist, and D. Mathis. 1993. Following a diabetogenic T cell from genesis through pathogenesis. Cell 74:1089.
25. + T cells in resistant mice upon infection with Leishmania major. Immunity 13:771.
26. Hoglund, P., J. Mintern, C. Waltzinger, W. Heath, C. Benoist, and D. Mathis. 1999. Initiation of autoimmune diabetes by developmentally regulated presentation of islet cell antigens in the pancreatic lymph nodes. J. Exp. Med. 189:331.
27. + T cells proliferating in response to influenza A antigen. J. Clin. Invest. 104:R63.
28. high, proliferating subset. Int. Immunol. 13:799.
29. Reijonen, H., E. J. Novak, S. Kochik, A. Heninger, A. W. Liu, W. W. Kwok, and G. T. Nepom. 2002. Detection of GAD65-specific T-cells by major histocompatibility complex class II tetramers in type I diabetic patients and at-risk subjects. Diabetes 51:1375.
30. Heath, W. R., C. Kurts, J. F. Miller, and F. R. Carbone. 1998. Cross-tolerance: a pathway for inducing tolerance to peripheral tissue antigens. J. Exp. Med. 187:1549.
31. + T cells undergo peripheral tolerance. Immunity 17:73.
32. Roncarolo, M. G., R. Bacchetta, C. Bordignon, S. Narula, and M. K. Levings. 2001. Type 1 T regulatory cells. Immunol. Rev. 182:68.
33. You, S., C. Chen, W. H. Lee, C. H. Wu, V. Judkowski, C. Pinilla, D. B. Wilson, and C. P. Liu. 2003. Detection and characterization of T cells specific for BDC2.5 T cell-stimulating peptides. J. Immunol. 170:4011.
34. Wegmann, D. R., M. Norbury-Glaser, and D. Daniel. 1994. Insulin-specific T cells are a predominant component of islet infiltrates in pre-diabetic NOD mice. Eur. J. Immunol. 24:1853.
35. Herold, K. C., J. B. Burton, F. Francois, E. Poumian-Ruiz, M. Glandt, and J. A. Bluestone. 2003. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3γ1(Ala-Ala). J. Clin. Invest. 111:409.